Iliopoulos, Othon

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature

Cancer, Hypoxia, and MetabolismCancer, Lipids, and Metabolism

Cited by 1,791

The Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1α

Zhong, L., D'Urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. D., Guimaraes, A., Marinelli, B., Wikstrom, J. D., Nir, T., et al. (2010) · Cell

Sirtuins and Resveratrol in MedicineMetabolism, Diabetes, and Cancer

Cited by 1,001

In Vivo HIF-Mediated Reductive Carboxylation Is Regulated by Citrate Levels and Sensitizes VHL-Deficient Cells to Glutamine Deprivation

Gameiro, P. A., Yang, J., Metelo, A. M., Pérez-Carro, R., Baker, R., Wang, Z., Arreola, A., Rathmell, W. K., Olumi, A., López-Larrubia, P., et al. (2013) · Cell Metabolism

Cancer, Hypoxia, and MetabolismCancer, Lipids, and Metabolism

Cited by 325

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors

Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 244

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell

Cancer, Hypoxia, and MetabolismRNA and protein synthesis mechanisms

Cited by 191

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 50

Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 42

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 22